A new nuclear reactor be approved by Dec 31, 2026 — Grants license priced at 3.9% on Kalshi, down 0.5 points, on $837K traded

Kalshi’s market on whether a new nuclear reactor will be approved by Dec 31, 2026 had its “Grants license” outcome priced at 3.9%, down 0.5 percentage points, with $837K traded. The supplied snapshot was published Oct 28, 2026 at 1:09 PM ET.

A lower price, without a fresh catalyst

The accompanying news-search summary identified no significant new platform headline in the preceding 30 minutes. It reported that search results contained only material already used that day, assigned to website-only batches or placed on a banned list. That provides no fresh reporting to explain the price decline.

The supplied source page also contains no reactor-specific regulatory update. The available material therefore supports a report on market pricing, rather than a conclusion that an approval decision or licensing development drove the move.

Reading the snapshot

According to predictionbubbles.net, its technology-market board displays market-implied probabilities, changes over the preceding 24 hours in percentage points, and total traded volume where the venue supplies it. The site refreshes its data every 15 minutes, while trading on the underlying venues continues between updates.

PredictionBubbles says it aggregates prices from Kalshi and Polymarket rather than accepting wagers itself. Its supplied page does not include the reactor contract’s detailed resolution rules, leaving the precise requirements for a qualifying approval unspecified in this material.

What it means for prediction markets

• The quoted probability is low: The 3.9% price reflects a low market-implied likelihood for the listed “Grants license” outcome by Dec 31, 2026, not an official assessment of approval prospects.
• Volume is not a catalyst: The $837K figure represents traded volume; it does not establish why the price fell 0.5 percentage points.
• Contract wording matters: Without the detailed resolution rules or fresh reactor-specific reporting, the snapshot cannot establish which licensing developments would satisfy the market.